Skip to main content
. 2022 Mar 17;6:16. doi: 10.1038/s41698-022-00260-0

Fig. 4. Alectinib-failure PDCs were resistant to multiple ALK-TKIs.

Fig. 4

Cell viability of ALK-positive PDCs treated with the indicated concentration of a alectinib, b lorlatinib, c crizotinib, and d ceritinib for 72 h was measured (n = 3). Each point represents the mean ± SD of three replicates.